Navigation Links
MIGENIX releases CEO message #22
Date:2/15/2008

ease contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and forward-looking information within the meaning of applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: Phase III OmigardTM trial results in the second half of 2008 and if the results of this trial are positive, a new drug application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering into Phase III clinical development, partnerships; and other progress expected in 2008 and into 2009.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the OmigardTM Phase III trial; the adequacy of the OmigardTM trial design to generate data that are deemed sufficient by regulatory authorities to support po
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
2. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
3. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
6. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/28/2014)... California, USA (PRWEB) August 28, 2014 ... Department of Physics and Optical Science and Director of ... University of North Carolina at Charlotte, and co-founder and ... elected to serve as the 2015 Vice President of ... SPIE 2014 President Philip Stahl announced recent election results ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... . From the motion sensor to the ... are used whose functioning is based on smallest structures of ... millimetres. These micro and nano structures must be manufactured and ... the overall system will function smoothly. Thereby, details are important ...
... OmniGuide, Inc., the developer of the first and only ... technology, today announced the results of a pre-clinical study ... in neurosurgery. In the study, surgeons from the Barrow ... in live brain tissue with fiber delivered CO2 laser ...
... HARBIN, China, July 6 /PRNewswire-Asia-FirstCall/ -- China ... a vertically integrated grower,developer, manufacturer and marketer ... that it has retained the services of ... China Kangtai will be,available through the Hawk ...
Cached Biology Technology:Nano measurement in the third dimension 2New Pre-Clinical Data on OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue 2New Pre-Clinical Data on OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue 3China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services 2China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services 3
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
(Date:8/28/2014)... , Aug. 28, 2014  Privacy Advocate and ... Jennifer Lynch , joins the lineup of biometric ... second annual Biometrics UnPlugged Executive Summit in ... Previously announced speakers include Steven Rahman, Director, Technology ... Public Sector at Experian. The theme of this year,s ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... Academy Research Fellow Michael Courtney has identified a new ... in the degeneration of brain cells, which in turn ... such as Alzheimer's disease, epilepsy and stroke. Courtney and ... of the University of Kuopio, joined forces with Docent ...
... at The University of Manchester believe injections of tiny ... in the treatment of chronic lower back pain. , ... Professor Tony Freemont from The Faculty of Medical and ... and stiffen when injected into a damaged area. ...
... tobacco company's description of its new cigarette brand seems to ... with smoking," the company boasts on its Web site, making ... to quit, but who are interested in a cigarette that ... tobacco firm, in a print ad for the brand, has ...
Cached Biology News:Researchers hot on the trail of brain cell degeneration 2Swell gel could bring relief to back pain sufferers 2New cigarette designs don't offer lower predicted cancer risks 2New cigarette designs don't offer lower predicted cancer risks 3
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... acid acceptor activity using aminoacyl-tRNA synthetase and a ... Lys, Pro, Thr, Val, Arg, Glu, His, Leu, ... will yield an A 260 of 1.0 ... path). Physical Form: lyophilized powder ...
... use as a carrier in ... Physical form: Solution in 10 ... 1 mM EDTA Preparation Note: ... Concentration: 10 mg/mL ...
... Cleland’s Reagent, Immobilized White solid. ... form of DTT on polyacrylamide resin with applications ... 233153 , 233156 , and ... no soluble components are added to the system. ...
Biology Products: